Forum for Science, Industry and Business

Sponsored by:     3M 
Search our Site:

 

Minor Depression Is Effectively Treated with Medication

05.10.2004


Minor depression, an underdiagnosed and undertreated subset of major depressive disorder that affects upwards of 15 million Americans*, can be effectively treated with a drug called a selective serotonin reuptake inhibitor (SSRI), according to a multi-center study led by the University of California, San Diego (UCSD) School of Medicine and published in the October 2004 issue of the American Journal of Psychiatry.



“This is especially important since patients with minor depression are not only at risk for significant psychosocial impairment, but for major depressive episodes that can be even more debilitating,” said the study’s lead author, Lewis L. Judd, M.D., professor of psychiatry and chair of the UCSD Department of Psychiatry

He added that unclear categories of illness and diagnosis in the past have led psychiatrists to generally consider minor depression to be a negligible condition that didn’t require any treatment. While some mental health professionals have considered minor depression to be a non-specific variation of normal mood, more recent studies have identified it as a clinically significant medical condition.**


Now, urging that minor depression can and should be treated, Judd said the new study of 162 patients with minor depressive disorder showed that patients given the SSRI fluoxetine (brand name Prozac) over a 12-week period showed significantly greater improvement in mood and psychosocial function as compared to depressed patients receiving a placebo. Several standard psychiatric tests were used to compare the results.***

The National Institute of Mental Health (NIMH) notes that minor depression is a common disorder that can impair a person’s functioning and quality of life, and serve as a serious risk factor for major depression. The difference between major and minor depression is the number of symptoms. Major depressive disorder includes the primary criteria of sadness plus at least five symptoms (such as insomnia, weight loss or gain, low energy, difficulty concentrating, reduction in sexual drive, suicidal ideas and/or behavior, psychomotor slowing, restlessness or irritability, inertia to initiate activity, and persistent physical symptoms, such as headache or digestive disorders, that don’t respond to treatment); minor depression includes the same primary sadness plus one or two additional symptoms.

Judd, a former director of the NIMH and a national expert on depression, said “minor depression is the same as or a less severe variant of major depressive disorder. Significantly, it doesn’t reach the threshold of a major depression. In previous studies, we’ve seen that depressive symptoms wax and wane over an individual’s lifetime, with most depressed patients usually suffering from minor depression more of the time than major depression.”

Because it impairs individuals, Judd and the other leaders of the study recommend treatment for minor depression, especially before it balloons into a major episode. His co-leaders and co-authors of the study were A. John Rush, M.D., University of Texas Southwestern Medical Center, Dallas; and David J. Kupfer, M.D., University of Pittsburgh.

The UCSD study coordinator and co-author of the paper was Mark H. Rapaport, M.D., then a member of the UCSD Department of Psychiatry and currently chair of the Department of Psychiatry at Cedars-Sinai Medical Center, Los Angeles, California. Rapaport noted that the study “is one of the first and largest studies to evaluate the efficacy of an SSRI in the treatment of a well characterized cohort of subjects with minor depression. It has shown us that treating less than major depression with an SSRI does work.”

Additional authors of the study were Kimberly A. Yonkers, M.D., Yale University School of Medicine; Ellen Frank, Ph.D. and Michael E. Thase, M.D., University of Pittsburgh; John M. Plewes, M.D., Pamela J. Schettler, Ph.D., and Gary Tollefson, M.D., Ph.D., Eli Lilly & Co.

The study was funded by an unrestricted investigator-initiated contract from Eli Lilly & Co. and by grants from the NIMH and the Roher Fund of the University of California, San Diego.

* Source = National Institute of Mental Health (NIMH)
The NIMH definition of depression: A depressive disorder is an illness that involves the body, mood, and thoughts. It affects the way a person eats and sleeps, the way one feels about oneself, and the way one thinks about things. A depressive disorder is not the same as a passing blue mood. It is not a sign of personal weakness or a condition that can be willed or wished away. People with a depressive illness cannot merely "pull themselves together" and get better. Without treatment, symptoms can last for weeks, months, or years. Appropriate treatment, however, can help most people who suffer from depression.

** American Journal of Psychiatry 2002, 159:637-643.

*** Inventory of Depressive Symptomatology, Hamilton Depression Rating Scale, Beck Depression Inventory, the Clinical Global Impression severity scale, and the Global Assessment of Functioning Scale.

| newswise
Further information:
http://www.ucsd.edu

More articles from Health and Medicine:

nachricht Penn vet research identifies new target for taming Ebola
12.01.2017 | University of Pennsylvania

nachricht The strange double life of Dab2
10.01.2017 | University of Miami Miller School of Medicine

All articles from Health and Medicine >>>

The most recent press releases about innovation >>>

Die letzten 5 Focus-News des innovations-reports im Überblick:

Im Focus: Designing Architecture with Solar Building Envelopes

Among the general public, solar thermal energy is currently associated with dark blue, rectangular collectors on building roofs. Technologies are needed for aesthetically high quality architecture which offer the architect more room for manoeuvre when it comes to low- and plus-energy buildings. With the “ArKol” project, researchers at Fraunhofer ISE together with partners are currently developing two façade collectors for solar thermal energy generation, which permit a high degree of design flexibility: a strip collector for opaque façade sections and a solar thermal blind for transparent sections. The current state of the two developments will be presented at the BAU 2017 trade fair.

As part of the “ArKol – development of architecturally highly integrated façade collectors with heat pipes” project, Fraunhofer ISE together with its partners...

Im Focus: How to inflate a hardened concrete shell with a weight of 80 t

At TU Wien, an alternative for resource intensive formwork for the construction of concrete domes was developed. It is now used in a test dome for the Austrian Federal Railways Infrastructure (ÖBB Infrastruktur).

Concrete shells are efficient structures, but not very resource efficient. The formwork for the construction of concrete domes alone requires a high amount of...

Im Focus: Bacterial Pac Man molecule snaps at sugar

Many pathogens use certain sugar compounds from their host to help conceal themselves against the immune system. Scientists at the University of Bonn have now, in cooperation with researchers at the University of York in the United Kingdom, analyzed the dynamics of a bacterial molecule that is involved in this process. They demonstrate that the protein grabs onto the sugar molecule with a Pac Man-like chewing motion and holds it until it can be used. Their results could help design therapeutics that could make the protein poorer at grabbing and holding and hence compromise the pathogen in the host. The study has now been published in “Biophysical Journal”.

The cells of the mouth, nose and intestinal mucosa produce large quantities of a chemical called sialic acid. Many bacteria possess a special transport system...

Im Focus: Newly proposed reference datasets improve weather satellite data quality

UMD, NOAA collaboration demonstrates suitability of in-orbit datasets for weather satellite calibration

"Traffic and weather, together on the hour!" blasts your local radio station, while your smartphone knows the weather halfway across the world. A network of...

Im Focus: Repairing defects in fiber-reinforced plastics more efficiently

Fiber-reinforced plastics (FRP) are frequently used in the aeronautic and automobile industry. However, the repair of workpieces made of these composite materials is often less profitable than exchanging the part. In order to increase the lifetime of FRP parts and to make them more eco-efficient, the Laser Zentrum Hannover e.V. (LZH) and the Apodius GmbH want to combine a new measuring device for fiber layer orientation with an innovative laser-based repair process.

Defects in FRP pieces may be production or operation-related. Whether or not repair is cost-effective depends on the geometry of the defective area, the tools...

All Focus news of the innovation-report >>>

Anzeige

Anzeige

Event News

12V, 48V, high-voltage – trends in E/E automotive architecture

10.01.2017 | Event News

2nd Conference on Non-Textual Information on 10 and 11 May 2017 in Hannover

09.01.2017 | Event News

Nothing will happen without batteries making it happen!

05.01.2017 | Event News

 
Latest News

Multiregional brain on a chip

16.01.2017 | Power and Electrical Engineering

New technology enables 5-D imaging in live animals, humans

16.01.2017 | Information Technology

Researchers develop environmentally friendly soy air filter

16.01.2017 | Power and Electrical Engineering

VideoLinks
B2B-VideoLinks
More VideoLinks >>>